Makindo Medical Notes"One small step for man, one large step for Makindo" |
![]() |
---|---|
Download all this content in the Apps now Android App and Apple iPhone/Pad App | |
MEDICAL DISCLAIMER: The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis, or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website. Makindo Ltd. |
Related Subjects: |Male Infertility |Prolactin |Prolactinoma |Sheehan's syndrome |Dopamine agonists
⚠️ Some ergot-derived dopamine agonists (e.g. cabergoline, pergolide, bromocriptine) have been associated with fibrotic reactions such as retroperitoneal fibrosis and valvular heart disease (↑ mitral, aortic, and tricuspid regurgitation). 💡 Non-ergot agonists are now preferred due to better safety profiles. Always check the BNF or local guidance for up-to-date prescribing advice.
💡 Pearls: - Always baseline and periodic echo if using ergot-derived agents. - Screen patients for history of psychiatric illness before starting. - Consider dopamine agonists in younger patients with Parkinson’s to delay levodopa-induced motor complications. - Monitor closely for impulse control disorders and counsel patients + families.